Physician profile
Anuja Rohatgi
NPI 1790728707
$445.35
in general payments reported to CMS, 2019-2025
9 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $119 · 2024: $186 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $425 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.13 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $123.17 | 2023-2025 | Wegovy |
| Lilly USA, LLC | $97.34 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $50.19 | 2024 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $47.66 | 2025 | |
| Astellas Pharma US INC | $42.67 | 2023 | Myrbetriq, Veozah |
| Abbott Laboratories | $32.20 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $20.24 | 2023 | Rexulti |
| Shield Therapeutics INC | $16.13 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $15.75 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anuja Rohatgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.